The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
International Journal of Endocrinology, 2014 Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes.
Se Hwa Kim +3 more
doaj +1 more source
Kidney & Blood Pressure Research, 2015 Background/Aims: Cardiovascular calcification contributes to the increased mortality in hemodialysis patients. Sclerostin was identified as an antianabolic bone factor causing soft tissue calcification. Data on prospective large-scale studies associating
Albina Nowak +6 more
doaj +1 more source
Iron-enriched diet contributes to early onset of osteoporotic phenotype in a mouse model of hereditary hemochromatosis [PDF]
, 2018 Osteoporosis is associated with chronic iron overload secondary to hereditary hemochromatosis (HH), but the causative mechanisms are incompletely understood.
Camacho, António +7 more
core +4 more sources
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Arthritis &Rheumatology, Accepted Article.Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami +10 more
wiley +1 more source
Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022 Background Myeloma bone disease (MBD) is a common complication that significantly contributes to morbidity and mortality in multiple myeloma (MM). Serum sclerostin level and sympathetic activity can affect MBD.
Alaa A. Omran +4 more
doaj +1 more source
Physical activity and hypocaloric diet recovers osteoblasts homeostasis in women affected by abdominal obesity. [PDF]
, 2016 Obesity is a multifactorial disease linked to metabolic chronic disorders such as diabetes, and hypertension. Also, it has recently been associated with skeletal alterations and low bone mineral density.
Baldari, C +13 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama +5 more
wiley +1 more source
Sclerostin: Current Knowledge and Future Perspectives [PDF]
Calcified Tissue International, 2010 In recent years study of rare human bone disorders has led to the identification of important signaling pathways that regulate bone formation. Such diseases include the bone sclerosing dysplasias sclerosteosis and van Buchem disease, which are due to deficiency of sclerostin, a protein secreted by osteocytes that inhibits bone formation by osteoblasts.
Moester, M.J.C. +3 more
openaire +3 more sources
Romosozumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia, 2018 Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality ...
Michael R. McClung
doaj +1 more source
Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]
, 2018 Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley +17 more
core +2 more sources